

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. (2023) www.uspto.gov

DATE MAILED: 03/13/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/897,412 07/03/2001		Richard J. Davis	620-148	8317
7.	590 03/13/2003			
NIXON & VANDERHYE P.C. 8th Floor 1100 North Glebe Road			EXAMINER	
			NICHOLS, CHRISTOPHER J 9	
Arlington, VA	22201		ART UNIT	PAPER NUMBER
			1647	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
Office Acti 2		09/897,412	DAVIS ET AL.
Office Action Sur	nmary	Examiner	Art Unit
		Christopher Nichols, Ph.D.	1647
The MAILING DATE of the Period for Reply	is communication app	ears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY THE MAILING DATE OF THIS  Extensions of time may be available under after SIX (6) MONTHS from the mailing date.  If the period for reply specified above is letter in NO period for reply is specified above, it is failure to reply within the set or extended.  Any reply received by the Office later than earned patent term adjustment. See 37 Cl.  Status	COMMUNICATION.  r the provisions of 37 CFR 1.13  ate of this communication.  ss than thirty (30) days, a reply  me maximum statutory period w  period for reply will, by statute,  three months after the mailing	36(a). In no event, however, may a replination within the statutory minimum of thirty (in the statutory and will expire SIX (6) MONTH cause the application to become APAN	ly be timely filed  30) days will be considered timely IS from the mailing date of this communication.
1) Responsive to communic	cation(s) filed on 23 A	lovember 2001	
2a) This action is <b>FINAL</b> .		s action is non-final.	
3) Since this application is in closed in accordance with	n condition for allowa		rs, prosecution as to the merits is
Disposition of Claims			,
4) Claim(s) 1-10 is/are pend			
4a) Of the above claim(s)		n from consideration.	
5) Claim(s) is/are allo			
6)☐ Claim(s) is/are reje	cted.		
7) Claim(s) is/are obje	ected to.		
8) Claim(s) <u>1-10</u> are subject Application Papers	to restriction and/or el	lection requirement.	
9)☐ The specification is objecte	ed to by the Evaminer		
10) The drawing(s) filed on <u>03</u> .	-		hy tha Evaminar
		drawing(s) be held in abeyance	
11) ☐ The proposed drawing corre		is: a) ☐ approved b) ☐ disa	
If approved, corrected draw			pproved by the Examiner.
12) The oath or declaration is o			
Priority under 35 U.S.C. §§ 119 and			
13) Acknowledgment is made		priority under 35 H.S.C. & 1:	19(a)-(d) or (f)
a)			10(a) (a) or (i).
	e priority documents	have been received	
		have been received in Appli	ication No
3. Copies of the certifie	d copies of the priority	y documents have been rec au (PCT Rule 17.2(a)).	eived in this National Stage
14) Acknowledgment is made of			
a)  The translation of the fo	oreign language provi	sional application has been	received.
ttachment(s)	2 2 3 7 3 4 3 5 1 1 3 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6	F. 13/11, and 01 00 0.0.0. 99	120 anu/01 121.
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Information Disclosure Statement(s) (PT	, Review (PTO-948) O-1449) Paper No(s)	5) Notice of Inform	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)
Patent and Trademark Office O-326 (Rev. 04-01)	Office Actic	on Summary	Part of Paper No. 9

Application/Control Number: 09/897,412 Page 2

Art Unit: 1647

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1, 3, 5, and 7, drawn to a method of treatment of cystic fibrosis in a patient comprising administering SEQ ID NO: 10, classified in class 514, subclass 2, for example.
  - II. Claims 2, 4, 6, and 8, drawn to a method of treatment of chronic obstructive pulmonary disease in a patient comprising administering SEQ ID NO: 10, classified in class 514, subclass 2, for example.
  - III. Claim 9, drawn to a composition comprising a secretin receptor ligand together with a least one other compound active against cystic fibrosis, classification dependent upon agent structure.
  - IV. Claim 10, drawn to a composition comprising a secretin receptor ligand together with a least one other compound active against chronic obstructive pulmonary disease, classification dependent upon agent structure.
- 2. The inventions are distinct, each from the other because of the following reasons:
- 3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to <u>different</u> methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions I and II are directed to methods that are distinct both

Application/Control Number: 09/897,412

Art Unit: 1647

Page 3

physically and functionally, and are not required one for the other. Invention I requires search and consideration of cystic fibrosis, which is not required by Invention II. Invention II requires search and consideration of chronic obstructive pulmonary disease, which is not required by Invention I.

- 4. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to <u>different</u> products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Inventions III and IV are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The composition of Invention III is independent and distinct from the product of Invention IV because it is not required to make the composition of Invention III. The composition of Invention IV is independent and distinct from the product of Invention III because it is not required to make the composition of Invention IV.
- 5. Inventions I and each of Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the method of Invention I does not recite the use or manufacture of the compositions of Inventions III or IV.
- 6. Inventions II and each of Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

Application/Control Number: 09/897,412

Page 4

Art Unit: 1647

In the instant case the method of Invention II does not recite the use or manufacture of the compositions of Inventions III or IV.

- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 8. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.
- 9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

. .

Application/Control Number: 09/897,412

Art Unit: 1647

Page 5

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher James Nichols, Ph.D. whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D. can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN March 4, 2003 Jau J. Kmz

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600